Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma Inc has enhanced its clinical and financial standing through the successful completion of an $8 million financing round, facilitating the advancement of its EB103 therapy into the Phase II portion of its study. The ongoing development of the EB104 dual CD19/CD22 program, alongside potential strategic partnerships, positions the company to address significant market opportunities in treating B-cell malignancies and autoimmune conditions. With encouraging early safety and efficacy results for EB103, including the onboarding of the first Phase II patient, Estrella’s innovative Artemis Technology platform is poised to unlock new avenues in CAR-T therapy, particularly for solid tumors, indicating a strong potential for future growth.

Bears say

Estrella Immunopharma Inc faces significant financial concerns, particularly regarding potential future dilution stemming from the ongoing stock decline. Modifications to financial assumptions have led to a reduction in target price from $16.0 to $8.0, indicating a more conservative financial outlook as the company evaluates its strategic priorities and pipeline development. The lack of clarity surrounding updates on partnering and development sequencing could further hinder investor confidence and the company’s market performance.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Feb 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.